Business

GSK Acquires Nuvalent for $9 Billion

Updated 2026-06-09 04:45 UTC 1 source Neutral

GlaxoSmithKline is in talks to acquire Nuvalent for over $9 billion, the largest biotech deal in a decade. The acquisition aims to bolster GSK's drug pipeline amid patent expirations.

Coverage timeline — 1 article

CNBC

GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT

The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.

2026-06-09 04:31 UTC